ClinicalTrials.gg
CompletedNCT06262932Updated Jan 22, 2025

Effectiveness of Repeated Amiodarone Dosing Regimen Versus Standard Dosing Regimen in Atrial Fibrillation Patient With Rapid Ventricular Response

A Phase 4 interventional study of Amiodarone in Atrial Fibrillation, sponsored by Police General Hospital, Thailand. Completed at 1 site in Thailand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-22.

Sponsored by Police General Hospital, Thailand · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to compare in atrial fibrillation patient with rapid ventricular response. The main question it aims to answer are Effectiveness of Repeated Amiodarone dosing regimen versus standard dosing regimen in Atrial fibrillation patient with rapid ventricular response Participants will receive Amiodarone iv treatment with different regimen

  • Repeated dosing regimen
  • Standard dosing regimen
02

Conditions studied

  • Atrial Fibrillation

Browse trials for

03

In context

Atrial Fibrillation

4,009 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

This study's enrollment of 24 is below the median of 150 across 2,476 interventional studies indexed under Atrial Fibrillation.

Browse Atrial Fibrillation studies →

Lead sponsor

Police General Hospital, Thailand is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age above 18 years old
  • Atrial fibrillation with rapid ventricular response patient (ventricular rate > 110)

Exclusion criteria

Exclusion Criteria:

  • Baseline interval (QTc) \< 500 msec
  • History of pulmonary fibrosis
  • History of Cirrhosis
  • Cardiac Index \<2.2 L/min/m2 or Cardiogenic shock
  • Unstable arrhythmia
  • Receive amiodarone within 3 months prior to present illness
  • Pregnancy
  • Amiodarone or Iodine allergy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    Repeated amiodarone bolus dosing regimen

    An Initial 150 mg IV amiodarone bolus should be given over a 15-minute period. If the heart rate is still over 110 minutes after the initial treatment, provide an additional 150 mg IV amiodarone bolus over a 15-minute period. During the first 24 hours, this bolus may be administered up to three times in total. Within 24 hours of finishing the first bolus dosage, 900 mg of amiodarone will be administered intravenously.

    Drug: Amiodarone

  • Active comparator
    Standard dosing regimen

    An Initial 150 mg IV amiodarone bolus should be given over a 15-minute period, then a 24-hour amiodarone loading infusion 900 mg over 24 hours

    Drug: Amiodarone

Interventions

  • Assess the effectiveness of repeated bolus dosing strategies of amiodarone.

06

What researchers measure

Primary outcomes

  1. Heart rate

    Percentage of patients who have Atrial fibrillation with rapid ventricular response, the percentage of patients who have heart rate below 110 bpms at 6 hours after receiving a repeated amiodarone bolus and loading dose regimen to the percentage of patients who have heart rate below 110 bpms at 6 hour after a conventional amiodarone IV loading dose regimen

    Time frame: 6-hours after receiving amiodarone bolus

Secondary outcomes

  1. Normal sinus rhythm at 24 hours

    Percentage of patients who develop Atrial fibrillation with rapid ventricular response, the percentage of patients who have converted to sinus rhythm at 24-hours after receiving a repeated amiodarone bolus and loading dose regimen to the percentage of patients who have converted to sinus rhythm after a conventional amiodarone IV loading dose regimen

    Time frame: 24-hours after receiving amiodarone bolus

  2. Heart rate

    Percentage of patients who have Atrial fibrillation with rapid ventricular response, the percentage of patients who have heart rate below 110 bpms at 24 hours after receiving a repeated amiodarone bolus and loading dose regimen to the percentage of patients who have heart rate below 110 bpms at 6 hour after a conventional amiodarone IV loading dose regimen

    Time frame: 24-hours after receiving amiodarone bolus

  3. Major adverse cardiovascular events

    Number of MACE \[MACE defined as acute myocardial infarction (AMI), stroke, or cardiovascular death\]

    Time frame: 30 days after receiving amiodarone bolus

  4. Phlebitis

    Rate of phlebitis complication during amiodarone infusion

    Time frame: 24-hours after receiving amiodarone bolus

  5. Changed in heart rate

    Compare number of total heart rate induction in patients who received a repeated amiodarone bolus and loading dose regimen and a conventional amiodarone IV loading dose regimen at 24 hrs

    Time frame: 24-hours after receiving amiodarone bolus

07

Study locations

1 site
  • Police general hospital
    Bangkok, 10330, Thailand
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Dec 2024, 7 months.

Of 129 non-industry phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's 7 months is below that.

Counting every sponsor, half of 141 studies reached it within 48 months; a quarter within 27 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2024
First posted
Feb 16, 2024
StartActual
May 1, 2024
Primary completionActual
Dec 31, 2024
CompletionActual
Dec 31, 2024
Last update
Jan 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06262932
Lead sponsor
Police General Hospital, Thailand
Responsible party
Chawit Lopimpisuth (Principal Investigator, Police General Hospital, Thailand) — Principal investigator
First posted
Feb 16, 2024
Start date
May 1, 2024
Primary completion
Dec 31, 2024
Completion
Dec 31, 2024
Last update
Jan 22, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amiodarone

Start the discussion